Home World News Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients... World News Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 385 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR With Longer Follow-Up, Trastuzumab Deruxtecan Continues to Demonstrate Superior Efficacy Over... June 27, 2024 Dwayne Johnson Sends Special “Moana” Message To 3-Yr-Old Battling Cancer. November 21, 2019 Progress in Treating Liver Cancer and Biliary Tract Cancer with Immunotherapy:... January 18, 2022 FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab... September 30, 2026 Load more HOT NEWS Holiday Coping and Enjoying Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... ESMO World Congress on Gastrointestinal Cancer 2022 Barcelona, Spain 29 June... “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain...
